Clinical updates, including trial initiations, enrollment status and data readouts and publications: BMS, Dynavax, Evaxion, Macrogenics, Modag, Oramed, Palvella, Rakuten, Revive, Serum Institute of India, Spectrum, Supernus.
TORONTO – An airway clearance device that uses acoustic sound waves to treat lung disorders and respiratory infections like cystic fibrosis (CF) is now being used to clear the lungs of patients suffering very badly from COVID-19. Developed by Montreal-based Dymedso Inc., more than 675 Frequencer acoustic devices currently being utilized across the world are assisting COVID-19 patients by removing mucous and secretions from their lungs and smaller airways.
NEW DELHI – India is taking a multipronged approach to developing and distributing vaccines against COVID-19, with at least 10 different products under development, domestically or through collaborations with foreign developers. Vaccinations are likely to begin early next year but, with a population of around 1.2 billion, it is unlikely India will be able to vaccinate everybody it needs to before the end of 2022.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acell, Artms, Medtronic, Products + Features, Quidel, Rapid Medical.
The U.S. FDA has granted emergency use authorization (EUA) for thousands of products for the COVID-19 pandemic, and the agency is legally required to advise companies of their post-pandemic options for new marketing authorization. Conversely, companies that fail to deal with inventory for expired EUAs may find themselves in the crosshairs of the FDA, whistleblowers, and federal and state attorneys, suggesting that manufacturers of devices should have a plan for dealing with unused inventories once the public health emergency comes to an end.
The BioWorld Drug Developers index is currently tracking up more than 9% in value so far this month and is on target, with a handful of trading days left before the end of the year, to close up over 35% for 2020, well ahead of the general markets.
The latest global regulatory news, changes and updates affecting biopharma, including: USPTO to expand diversity in innovation; Opioid prescriptions could cost Walmart billions.
RSS
